$TOVX
Theriva Biologics, Inc.

2016 Q3 Form 10-Q Financial Statement

#000114420416130708 Filed on November 01, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2015 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.100M $1.600M
YoY Change 31.25% 31.15%
% of Gross Profit
Research & Development $7.061M $10.05M
YoY Change -29.71% 172.03%
% of Gross Profit
Depreciation & Amortization $50.00K $20.00K
YoY Change 150.0%
% of Gross Profit
Operating Expenses $9.156M $11.65M
YoY Change -21.41% 137.22%
Operating Profit -$9.156M -$11.65M
YoY Change -21.41% 137.22%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $667.0K $4.143M
YoY Change -83.9% 414200.0%
Pretax Income -$9.156M -$11.65M
YoY Change -21.41% 137.22%
Income Tax
% Of Pretax Income
Net Earnings -$8.489M -$7.507M
YoY Change 13.08% 52.89%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.08
Diluted Earnings Per Share -$0.09 -$0.12
COMMON SHARES
Basic Shares Outstanding 91.44M shares 85.97M shares
Diluted Shares Outstanding 91.44M shares 87.59M shares

Balance Sheet

Concept 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.550M $31.81M
YoY Change -85.7% 866.87%
Cash & Equivalents $4.549M $31.81M
Short-Term Investments
Other Short-Term Assets $294.0K $10.33M
YoY Change -97.15% 647.54%
Inventory
Prepaid Expenses $227.0K
Receivables
Other Receivables
Total Short-Term Assets $7.640M $42.14M
YoY Change -81.87% 802.68%
LONG-TERM ASSETS
Property, Plant & Equipment $580.0K $483.0K
YoY Change 20.08% 620.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $30.00K $10.00K
YoY Change 200.0% 0.0%
Total Long-Term Assets $610.0K $497.0K
YoY Change 22.74% 580.82%
TOTAL ASSETS
Total Short-Term Assets $7.640M $42.14M
Total Long-Term Assets $610.0K $497.0K
Total Assets $8.250M $42.63M
YoY Change -80.65% 799.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.240M $6.026M
YoY Change -29.64% 590.26%
Accrued Expenses $2.830M $244.0K
YoY Change 1059.84% 119.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.01M $17.30M
YoY Change -19.02% 1658.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $210.0K $200.0K
YoY Change 5.0%
Total Long-Term Liabilities $210.0K $200.0K
YoY Change 5.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.01M $17.30M
Total Long-Term Liabilities $210.0K $200.0K
Total Liabilities $12.72M $17.50M
YoY Change -27.31% 1678.35%
SHAREHOLDERS EQUITY
Retained Earnings -$133.8M
YoY Change 41.49%
Common Stock $159.7M
YoY Change 62.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.480M $25.87M
YoY Change
Total Liabilities & Shareholders Equity $8.250M $42.63M
YoY Change -80.65% 799.26%

Cashflow Statement

Concept 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$8.489M -$7.507M
YoY Change 13.08% 52.89%
Depreciation, Depletion And Amortization $50.00K $20.00K
YoY Change 150.0%
Cash From Operating Activities -$5.990M -$15.21M
YoY Change -60.62% 235.76%
INVESTING ACTIVITIES
Capital Expenditures -$150.0K -$400.0K
YoY Change -62.5% 1900.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$150.0K -$400.0K
YoY Change -62.5% 1900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 640.0K 42.66M
YoY Change -98.5%
NET CHANGE
Cash From Operating Activities -5.990M -15.21M
Cash From Investing Activities -150.0K -400.0K
Cash From Financing Activities 640.0K 42.66M
Net Change In Cash -5.500M 27.05M
YoY Change -120.33% -694.51%
FREE CASH FLOW
Cash From Operating Activities -$5.990M -$15.21M
Capital Expenditures -$150.0K -$400.0K
Free Cash Flow -$5.840M -$14.81M
YoY Change -60.57% 228.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3906000 USD
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1604000 USD
CY2015Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4141000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2095000 USD
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10046000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7061000 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
11650000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
9156000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11650000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9156000 USD
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 USD
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4143000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
667000 USD
CY2015Q3 us-gaap Profit Loss
ProfitLoss
-7507000 USD
CY2016Q3 us-gaap Profit Loss
ProfitLoss
-8489000 USD
CY2015Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-733000 USD
CY2016Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-136000 USD
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-666000 USD
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3681000 USD
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91441687 shares
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85974751 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91095990 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77300375 shares
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91441687 shares
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87585103 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91095990 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77300375 shares
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Share Based Compensation
ShareBasedCompensation
2906000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2059000 USD
syn Stock Issued For Milestone Payments
StockIssuedForMilestonePayments
0 USD
syn Stock Issued For Milestone Payments
StockIssuedForMilestonePayments
-1350000 USD
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1063000 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-23000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
814000 USD
us-gaap Depreciation
Depreciation
111000 USD
us-gaap Depreciation
Depreciation
39000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6428000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8783000 USD
syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
12000 USD
syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
8000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-171000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5030000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1193000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1054000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-224000 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
253000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17517000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-27920000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
199000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
457000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-199000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-457000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1447000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
42658000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-16269000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
14281000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17525000 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31806000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2016Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1300000 USD
CY2015Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
5300000 USD
CY2016Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8353000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24880000 USD
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8353000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24880000 USD
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6774000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32755000 USD
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10915000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-32755000 USD
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
50000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
CY2015 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
2448 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
63447 shares
CY2015 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
1.6
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.79
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7974794 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7908899 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7858899 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.79
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.77
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5700000 USD
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
191000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
105000 USD
CY2016Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1065000 USD
CY2015Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0 USD
CY2016Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
193000 USD
CY2015Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
153000 USD
CY2016Q3 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
83000 USD
CY2015Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
124000 USD
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1341000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
277000 USD
CY2015Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
0 USD
CY2016Q3 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
191000 USD
CY2015Q4 syn Accrued Vendor Payments
AccruedVendorPayments
133000 USD
CY2016Q3 syn Accrued Vendor Payments
AccruedVendorPayments
341000 USD
CY2015Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
164000 USD
CY2016Q3 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
935000 USD
CY2016Q3 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
0 USD
CY2015Q4 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
643000 USD
CY2016Q3 us-gaap Prepaid Insurance
PrepaidInsurance
75000 USD
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
339000 USD
CY2016Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
547000 USD
CY2015Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
208000 USD
CY2016Q3 syn Prepaid Clinical Research Organizations
PrepaidClinicalResearchOrganizations
2175000 USD
CY2015Q4 syn Prepaid Clinical Research Organizations
PrepaidClinicalResearchOrganizations
8329000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Synthetic Biologics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
SYN
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
92172714 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91733833 shares
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91652351 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90908234 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90826752 shares
syn Issue Of Stock For Exclusive Channel Collaboration Agreement
IssueOfStockForExclusiveChannelCollaborationAgreement
0 USD
syn Issue Of Stock For Exclusive Channel Collaboration Agreement
IssueOfStockForExclusiveChannelCollaborationAgreement
-3000000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46000000 USD
syn Direct Offering Cost
DirectOfferingCost
0 USD
syn Direct Offering Cost
DirectOfferingCost
3357000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
633000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
15000 USD
CY2016Q3 us-gaap Other Assets Current
OtherAssetsCurrent
294000 USD
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
0 USD
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
23000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2016Q3 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2015Q3 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2015Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1610352 shares
syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2015Q3 syn Warrant Liabilities
WarrantLiabilities
10700000 USD
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
773000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
599000 USD

Files In Submission

Name View Source Status
0001144204-16-130708-index-headers.html Edgar Link pending
0001144204-16-130708-index.html Edgar Link pending
0001144204-16-130708.txt Edgar Link pending
0001144204-16-130708-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20160930.xml Edgar Link completed
syn-20160930.xsd Edgar Link pending
syn-20160930_cal.xml Edgar Link unprocessable
syn-20160930_def.xml Edgar Link unprocessable
syn-20160930_lab.xml Edgar Link unprocessable
syn-20160930_pre.xml Edgar Link unprocessable
v450745_10q.htm Edgar Link pending
v450745_ex31-1.htm Edgar Link pending
v450745_ex31-2.htm Edgar Link pending
v450745_ex32-1.htm Edgar Link pending
v450745_ex32-2.htm Edgar Link pending